Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 441

1.

Increased reporting of fatal hepatitis associated with immune checkpoint inhibitors.

Vozy A, De Martin E, Johnson DB, Lebrun-Vignes B, Moslehi JJ, Salem JE.

Eur J Cancer. 2019 Oct 31;123:112-115. doi: 10.1016/j.ejca.2019.09.022. [Epub ahead of print] No abstract available.

PMID:
31678768
2.

Enrichment and isolation of acid-tolerant sulfate-reducing microorganisms in the anoxic, acidic hot spring sediments from Copahue volcano, Argentina.

Willis G, Nancucheo I, Hedrich S, Giaveno A, Donati E, Johnson DB.

FEMS Microbiol Ecol. 2019 Oct 30. pii: fiz175. doi: 10.1093/femsec/fiz175. [Epub ahead of print]

PMID:
31665270
3.

Dissimilatory reduction of sulfate and zero-valent sulfur at low pH and its significance for bioremediation and metal recovery.

Johnson DB, Sánchez-Andrea I.

Adv Microb Physiol. 2019;75:205-231. doi: 10.1016/bs.ampbs.2019.07.002. Epub 2019 Oct 10.

PMID:
31655738
4.

Targeted Therapy in Advanced Melanoma With Rare BRAF Mutations.

Menzer C, Menzies AM, Carlino MS, Reijers I, Groen EJ, Eigentler T, de Groot JWB, van der Veldt AAM, Johnson DB, Meiss F, Schlaak M, Schilling B, Westgeest HM, Gutzmer R, Pföhler C, Meier F, Zimmer L, Suijkerbuijk KPM, Haalck T, Thoms KM, Herbschleb K, Leichsenring J, Menzer A, Kopp-Schneider A, Long GV, Kefford R, Enk A, Blank CU, Hassel JC.

J Clin Oncol. 2019 Oct 3:JCO1900489. doi: 10.1200/JCO.19.00489. [Epub ahead of print]

PMID:
31580757
5.

Health care utilization and steroid-refractory toxicities from immune checkpoint inhibitors.

Wang LX, Quach HT, Moodabigil NV, Davis EJ, Sosman JA, Dusetzina SB, Johnson DB.

Cancer. 2019 Oct 3. doi: 10.1002/cncr.32542. [Epub ahead of print]

PMID:
31580492
6.

Cardiovascular Toxicities Associated With Ibrutinib.

Salem JE, Manouchehri A, Bretagne M, Lebrun-Vignes B, Groarke JD, Johnson DB, Yang T, Reddy NM, Funck-Brentano C, Brown JR, Roden DM, Moslehi JJ.

J Am Coll Cardiol. 2019 Oct 1;74(13):1667-1678. doi: 10.1016/j.jacc.2019.07.056.

PMID:
31558250
7.

Longer Survival With Anti-Programmed Cell Death 1 and Development of Cutaneous Toxic Effects, an Expected Association-In Reply.

Johnson DB, Ye F, Dewan AK.

JAMA Oncol. 2019 Sep 26. doi: 10.1001/jamaoncol.2019.3817. [Epub ahead of print] No abstract available.

PMID:
31556913
8.

Fatal hepatic necrosis after nivolumab as a bridge to liver transplant for HCC: Are checkpoint inhibitors safe for the pretransplant patient?

Nordness MF, Hamel S, Godfrey CM, Shi C, Johnson DB, Goff LW, O'Dell H, Perri RE, Alexopoulos SP.

Am J Transplant. 2019 Sep 24. doi: 10.1111/ajt.15617. [Epub ahead of print]

PMID:
31550417
9.

Anti-PD-1-Induced Pneumonitis Is Associated with Persistent Imaging Abnormalities in Melanoma Patients.

Johnson DB, Taylor KB, Cohen JV, Ayoubi N, Haugh AM, Wang DY, Schlick BD, Voorhees AL, Gage KL, Fintelmann FJ, Sullivan RJ, Eroglu Z, Abramson RG.

Cancer Immunol Res. 2019 Nov;7(11):1755-1759. doi: 10.1158/2326-6066.CIR-18-0717. Epub 2019 Aug 28.

PMID:
31462410
10.

Pseudoaneurysm of the Pancreaticoduodenal Artery Associated with Duodenal Diverticulitis.

Hao SB, Johnson DB, Bonatti HJR.

Case Rep Surg. 2019 Jul 22;2019:2831234. doi: 10.1155/2019/2831234. eCollection 2019.

11.

MDM2 antagonists overcome intrinsic resistance to CDK4/6 inhibition by inducing p21.

Vilgelm AE, Saleh N, Shattuck-Brandt R, Riemenschneider K, Slesur L, Chen SC, Johnson CA, Yang J, Blevins A, Yan C, Johnson DB, Al-Rohil RN, Halilovic E, Kauffmann RM, Kelley M, Ayers GD, Richmond A.

Sci Transl Med. 2019 Aug 14;11(505). pii: eaav7171. doi: 10.1126/scitranslmed.aav7171.

PMID:
31413145
12.

Myocarditis in the Setting of Cancer Therapeutics: Proposed Case Definitions for Emerging Clinical Syndromes in Cardio-Oncology

Bonaca MP, Olenchock BA, Salem JE, Wiviott SD, Ederhy S, Cohen A, Stewart GC, Choueiri TK, Di Carli M, Allenbach Y, Kumbhani DJ, Heinzerling L, Amiri-Kordestani L, Lyon AR, Thavendiranathan P, Padera R, Lichtman A, Liu PP, Johnson DB, Moslehi J.

Circulation. 2019 Jul 2;140(2):80-91.

PMID:
31390169
13.

A case report of clonal EBV-like memory CD4+ T cell activation in fatal checkpoint inhibitor-induced encephalitis.

Johnson DB, McDonnell WJ, Gonzalez-Ericsson PI, Al-Rohil RN, Mobley BC, Salem JE, Wang DY, Sanchez V, Wang Y, Chastain CA, Barker K, Liang Y, Warren S, Beechem JM, Menzies AM, Tio M, Long GV, Cohen JV, Guidon AC, O'Hare M, Chandra S, Chowdhary A, Lebrun-Vignes B, Goldinger SM, Rushing EJ, Buchbinder EI, Mallal SA, Shi C, Xu Y, Moslehi JJ, Sanders ME, Sosman JA, Balko JM.

Nat Med. 2019 Aug;25(8):1243-1250. doi: 10.1038/s41591-019-0523-2. Epub 2019 Jul 22.

PMID:
31332390
14.

Comparison of Biomarker Modalities for Predicting Response to PD-1/PD-L1 Checkpoint Blockade: A Systematic Review and Meta-analysis.

Lu S, Stein JE, Rimm DL, Wang DW, Bell JM, Johnson DB, Sosman JA, Schalper KA, Anders RA, Wang H, Hoyt C, Pardoll DM, Danilova L, Taube JM.

JAMA Oncol. 2019 Jul 18. doi: 10.1001/jamaoncol.2019.1549. [Epub ahead of print]

PMID:
31318407
15.

Acidithiobacillus sulfuriphilus sp. nov.: an extremely acidophilic sulfur-oxidizing chemolithotroph isolated from a neutral pH environment.

Falagán C, Moya-Beltrán A, Castro M, Quatrini R, Johnson DB.

Int J Syst Evol Microbiol. 2019 Sep;69(9):2907-2913. doi: 10.1099/ijsem.0.003576.

PMID:
31274405
16.

Correlates of response and outcomes with talimogene laherperpvec.

Zhou AY, Wang DY, McKee S, Ye F, Wen CC, Wallace DE, Ancell KK, Conry RM, Johnson DB.

J Surg Oncol. 2019 Sep;120(3):558-564. doi: 10.1002/jso.25601. Epub 2019 Jul 2.

PMID:
31264725
17.

Empiric Therapy with BRAF and MEK Inhibitors in Metastatic Melanoma.

Cann CG, Tillman BF, Davis EJ, Johnson DB.

Oncologist. 2019 Jun 18. pii: theoncologist.2019-0332. doi: 10.1634/theoncologist.2019-0332. [Epub ahead of print]

PMID:
31213499
18.

Abatacept for Severe Immune Checkpoint Inhibitor-Associated Myocarditis.

Salem JE, Allenbach Y, Vozy A, Brechot N, Johnson DB, Moslehi JJ, Kerneis M.

N Engl J Med. 2019 Jun 13;380(24):2377-2379. doi: 10.1056/NEJMc1901677. No abstract available.

PMID:
31189043
19.

Displaced Meniscus Tear in the Acute Postoperative Period After Total Hip Arthroplasty: A Case Report.

Johnson DB Jr, Triplet JJ, Streit AR, Long NK, Wasielewski RC.

JBJS Case Connect. 2019 Apr-Jun;9(2):e0124. doi: 10.2106/JBJS.CC.18.00124.

PMID:
31188794
20.

Identification of Targetable Recurrent MAP3K8 Rearrangements in Melanomas Lacking Known Driver Mutations.

Lehmann BD, Shaver TM, Johnson DB, Li Z, Gonzalez-Ericsson PI, Sánchez V, Shyr Y, Sanders ME, Pietenpol JA.

Mol Cancer Res. 2019 Sep;17(9):1842-1853. doi: 10.1158/1541-7786.MCR-19-0257. Epub 2019 Jun 11.

PMID:
31186280
21.

Upconversion of Cellulosic Waste Into a Potential "Drop in Fuel" via Novel Catalyst Generated Using Desulfovibrio desulfuricans and a Consortium of Acidophilic Sulfidogens.

Mikheenko IP, Gomez-Bolivar J, Merroun ML, Macaskie LE, Sharma S, Walker M, Hand RA, Grail BM, Johnson DB, Orozco RL.

Front Microbiol. 2019 May 10;10:970. doi: 10.3389/fmicb.2019.00970. eCollection 2019.

22.

Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study.

Johnson DB, Manouchehri A, Haugh AM, Quach HT, Balko JM, Lebrun-Vignes B, Mammen A, Moslehi JJ, Salem JE.

J Immunother Cancer. 2019 May 22;7(1):134. doi: 10.1186/s40425-019-0617-x.

23.

Immunotherapy in Older Adults with Cancer.

Godby RC, Johnson DB, Williams GR.

Curr Oncol Rep. 2019 May 7;21(7):56. doi: 10.1007/s11912-019-0806-2. Review.

PMID:
31065907
24.

Tumor genomic alterations in severe-combined immunodeficiency bare-lymphocyte syndrome genes are associated with high mutational burden and disproportional neo-antigen rates.

Wang Y, Johnson DB, Lu S, Diaz LA Jr, Xu Y, Balko JM.

J Immunother Cancer. 2019 May 7;7(1):123. doi: 10.1186/s40425-019-0584-2.

25.

Association of Anti-Programmed Cell Death 1 Cutaneous Toxic Effects With Outcomes in Patients With Advanced Melanoma.

Quach HT, Dewan AK, Davis EJ, Ancell KK, Fan R, Ye F, Johnson DB.

JAMA Oncol. 2019 Jun 1;5(6):906-908. doi: 10.1001/jamaoncol.2019.0046. No abstract available.

PMID:
30998826
26.

Immune checkpoint inhibitor-associated hypophysitis-World Health Organisation VigiBase report analysis.

Guerrero E, Johnson DB, Bachelot A, Lebrun-Vignes B, Moslehi JJ, Salem JE.

Eur J Cancer. 2019 May;113:10-13. doi: 10.1016/j.ejca.2019.03.002. Epub 2019 Apr 4. No abstract available.

PMID:
30954881
27.

Severe Epididymo-Orchitis and Encephalitis Complicating Anti-PD-1 Therapy.

Quach HT, Robbins CJ, Balko JM, Chiu CY, Miller S, Wilson MR, Nelson GE, Johnson DB.

Oncologist. 2019 Jul;24(7):872-876. doi: 10.1634/theoncologist.2018-0722. Epub 2019 Apr 1.

PMID:
30936376
28.

Adverse Events Associated With Immune Checkpoint Inhibitors-Reply.

Johnson DB, Chandra S, Sosman JA.

JAMA. 2019 Mar 26;321(12):1219-1220. doi: 10.1001/jama.2018.22123. No abstract available.

PMID:
30912830
29.

Mid-term outcomes following primary semi-constrained total knee arthroplasty in patients less than 60 years old, a retrospective review.

Johnson DB Jr, Triplet JJ, Gaines DR, Gupta A, Unverferth KL.

Knee. 2019 Jun;26(3):714-719. doi: 10.1016/j.knee.2019.02.001. Epub 2019 Mar 19.

PMID:
30902516
30.

Clinical Correlates of Response to Anti-PD-1-based Therapy in Patients With Metastatic Melanoma.

Davis EJ, Perez MC, Ayoubi N, Zhao S, Ye F, Wang DY, Sosman JA, Al-Rohil RN, Eroglu Z, Johnson DB.

J Immunother. 2019 Jul/Aug;42(6):221-227. doi: 10.1097/CJI.0000000000000258.

PMID:
30882548
31.

Validation of a Two-Item Food Security Screening Tool in a Dental Setting.

Radandt NE, Corbridge T, Johnson DB, Kim AS, Scott JM, Coldwell SE.

J Dent Child (Chic). 2018 Sep 15;85(3):114-119.

32.

Hematologic Complications of Immune Checkpoint Inhibitors.

Davis EJ, Salem JE, Young A, Green JR, Ferrell PB, Ancell KK, Lebrun-Vignes B, Moslehi JJ, Johnson DB.

Oncologist. 2019 May;24(5):584-588. doi: 10.1634/theoncologist.2018-0574. Epub 2019 Feb 28.

33.

Retrograde Femoral Bone Graft Acquisition Using the Reamer-Irrigator-Aspirator.

Taylor BC, Triplet JJ, Johnson DB, Sharpe BD, Sullivan B, Canini C.

J Long Term Eff Med Implants. 2018;28(3):181-185. doi: 10.1615/JLongTermEffMedImplants.2018027914.

PMID:
30806274
34.

Clinical and laboratory features of autoimmune hemolytic anemia associated with immune checkpoint inhibitors.

Leaf RK, Ferreri C, Rangachari D, Mier J, Witteles W, Ansstas G, Anagnostou T, Zubiri L, Piotrowska Z, Oo TH, Iberri D, Yarchoan M, Salama AKS, Johnson DB, Leavitt AD, Rahma OE, Reynolds KL, Leaf DE.

Am J Hematol. 2019 May;94(5):563-574. doi: 10.1002/ajh.25448. Epub 2019 Mar 13.

PMID:
30790338
35.

Response to Anti-PD-1 in Uveal Melanoma Without High-Volume Liver Metastasis.

Johnson DB, Bao R, Ancell KK, Daniels AB, Wallace D, Sosman JA, Luke JJ.

J Natl Compr Canc Netw. 2019 Feb;17(2):114-117. doi: 10.6004/jnccn.2018.7070.

PMID:
30787124
36.

Loss of BOP1 confers resistance to BRAF kinase inhibitors in melanoma by activating MAP kinase pathway.

Gupta R, Bugide S, Wang B, Green MR, Johnson DB, Wajapeyee N.

Proc Natl Acad Sci U S A. 2019 Mar 5;116(10):4583-4591. doi: 10.1073/pnas.1821889116. Epub 2019 Feb 19.

37.

Incidence, features and management of radionecrosis in melanoma patients treated with cerebral radiotherapy and anti-PD-1 antibodies.

Pires da Silva I, Glitza IC, Haydu LE, Johnpulle R, Banks PD, Grass GD, Goldinger SMA, Smith JL, Everett AS, Koelblinger P, Roberts-Thomson R, Millward M, Atkinson VG, Guminski A, Kapoor R, Conry RM, Carlino MS, Wang W, Shackleton MJ, Eroglu Z, Lo S, Hong AM, Long GV, Johnson DB, Menzies AM.

Pigment Cell Melanoma Res. 2019 Jul;32(4):553-563. doi: 10.1111/pcmr.12775. Epub 2019 Mar 3.

PMID:
30767428
38.

Targeting tissue factor in advanced solid tumours.

Davis EJ, Johnson DB.

Lancet Oncol. 2019 Mar;20(3):318-319. doi: 10.1016/S1470-2045(18)30912-4. Epub 2019 Feb 8. No abstract available.

PMID:
30745091
39.

Cardiovascular toxicities associated with immune checkpoint inhibitors.

Hu JR, Florido R, Lipson EJ, Naidoo J, Ardehali R, Tocchetti CG, Lyon AR, Padera RF, Johnson DB, Moslehi J.

Cardiovasc Res. 2019 Apr 15;115(5):854-868. doi: 10.1093/cvr/cvz026. Erratum in: Cardiovasc Res. 2019 Apr 15;115(5):868.

PMID:
30715219
40.

A phase 2 study of glembatumumab vedotin, an antibody-drug conjugate targeting glycoprotein NMB, in patients with advanced melanoma.

Ott PA, Pavlick AC, Johnson DB, Hart LL, Infante JR, Luke JJ, Lutzky J, Rothschild NE, Spitler LE, Cowey CL, Alizadeh AR, Salama AK, He Y, Hawthorne TR, Bagley RG, Zhang J, Turner CD, Hamid O.

Cancer. 2019 Apr 1;125(7):1113-1123. doi: 10.1002/cncr.31892. Epub 2019 Jan 28.

PMID:
30690710
41.

Isolated Treatment of a Comminuted Capitate Fracture: A Case Report.

Johnson DB Jr, Triplet JJ, Bernhardt L, Buchan DR, Iorio T.

JBJS Case Connect. 2019 Jan-Mar;9(1):e6. doi: 10.2106/JBJS.CC.18.00166.

PMID:
30676344
42.

Endosomolytic polymersomes increase the activity of cyclic dinucleotide STING agonists to enhance cancer immunotherapy.

Shae D, Becker KW, Christov P, Yun DS, Lytton-Jean AKR, Sevimli S, Ascano M, Kelley M, Johnson DB, Balko JM, Wilson JT.

Nat Nanotechnol. 2019 Mar;14(3):269-278. doi: 10.1038/s41565-018-0342-5. Epub 2019 Jan 21.

43.

The Prognostic Significance of Low-Frequency Somatic Mutations in Metastatic Cutaneous Melanoma.

Zhao X, Little P, Hoyle AP, Pegna GJ, Hayward MC, Ivanova A, Parker JS, Marron DL, Soloway MG, Jo H, Salazar AH, Papakonstantinou MP, Bouchard DM, Jefferys SR, Hoadley KA, Ollila DW, Frank JS, Thomas NE, Googe PB, Ezzell AJ, Collichio FA, Lee CB, Earp HS, Sharpless NE, Hugo W, Wilmott JS, Quek C, Waddell N, Johansson PA, Thompson JF, Hayward NK, Mann GJ, Lo RS, Johnson DB, Scolyer RA, Hayes DN, Moschos SJ.

Front Oncol. 2019 Jan 4;8:584. doi: 10.3389/fonc.2018.00584. eCollection 2018.

44.

Distinct Molecular Profiles and Immunotherapy Treatment Outcomes of V600E and V600K BRAF-Mutant Melanoma.

Pires da Silva I, Wang KYX, Wilmott JS, Holst J, Carlino MS, Park JJ, Quek C, Wongchenko M, Yan Y, Mann G, Johnson DB, McQuade JL, Rai R, Kefford RF, Rizos H, Scolyer RA, Yang JYH, Long GV, Menzies AM.

Clin Cancer Res. 2019 Feb 15;25(4):1272-1279. doi: 10.1158/1078-0432.CCR-18-1680. Epub 2019 Jan 10.

PMID:
30630828
45.

Nontraumatic Compartment Syndrome in a Patient with Protein S Deficiency: A Case Report.

Pentz K, Triplet JJ, Johnson DB, Umbel B, Baker TE.

JBJS Case Connect. 2018 Oct-Dec;8(4):e82. doi: 10.2106/JBJS.CC.18.00055.

PMID:
30601765
46.

Biomarkers for Immunotherapy Toxicity: Are Cytokines the Answer?

Johnson DB, Balko JM.

Clin Cancer Res. 2019 Mar 1;25(5):1452-1454. doi: 10.1158/1078-0432.CCR-18-3858. Epub 2018 Dec 26.

PMID:
30587548
47.

Tumor-specific MHC-II expression drives a unique pattern of resistance to immunotherapy via LAG-3/FCRL6 engagement.

Johnson DB, Nixon MJ, Wang Y, Wang DY, Castellanos E, Estrada MV, Ericsson-Gonzalez PI, Cote CH, Salgado R, Sanchez V, Dean PT, Opalenik SR, Schreeder DM, Rimm DL, Kim JY, Bordeaux J, Loi S, Horn L, Sanders ME, Ferrell PB Jr, Xu Y, Sosman JA, Davis RS, Balko JM.

JCI Insight. 2018 Dec 20;3(24). pii: 120360. doi: 10.1172/jci.insight.120360.

48.

Acidithiobacillus ferrooxidans.

Quatrini R, Johnson DB.

Trends Microbiol. 2019 Mar;27(3):282-283. doi: 10.1016/j.tim.2018.11.009. Epub 2018 Dec 15.

PMID:
30563727
49.

Clinical characterization of colitis arising from anti-PD-1 based therapy.

Wang DY, Mooradian MJ, Kim D, Shah NJ, Fenton SE, Conry RM, Mehta R, Silk AW, Zhou A, Compton ML, Al-Rohil RN, Lee S, Voorhees AL, Ha L, McKee S, Norrell JT, Mehnert J, Puzanov I, Sosman JA, Chandra S, Gibney GT, Rapisuwon S, Eroglu Z, Sullivan R, Johnson DB.

Oncoimmunology. 2018 Oct 31;8(1):e1524695. doi: 10.1080/2162402X.2018.1524695. eCollection 2019.

50.

Tolerance and efficacy of BRAF plus MEK inhibition in patients with melanoma who previously have received programmed cell death protein 1-based therapy.

Saab KR, Mooradian MJ, Wang DY, Chon J, Xia CY, Bialczak A, Abbate KT, Menzies AM, Johnson DB, Sullivan RJ, Shoushtari AN.

Cancer. 2019 Mar 15;125(6):884-891. doi: 10.1002/cncr.31889. Epub 2018 Dec 6.

PMID:
30521084

Supplemental Content

Loading ...
Support Center